Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 120,000 shares at a total cost of HKD 307,800 [1] - The buyback price per share ranges from HKD 2.55 to HKD 2.58 [1]

智通财经APP讯，朝聚眼科(02219)发布公告，于2025年11月19日，该公司斥资30.78万港元回购12万股 股份，每股回购价格为2.55-2.58港元。 ...

格隆汇11月19日丨朝聚眼科(02219.HK)公告，11月19日耗资30.8万港元回购12万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 朝聚眼科醫療控股有限公司 呈交日期： 2025年11月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02219 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（ ...

每经AI快讯，朝聚眼科(02219.HK)涨超4%，截至发稿，涨4.07%，报2.56港元，成交额138.51万港元。 ...

Core Viewpoint - 朝聚眼科 (02219) announced a share buyback plan, reflecting confidence in its business outlook and aiming to create value for shareholders [1] Group 1: Share Buyback Announcement - The company plans to repurchase up to HKD 50 million worth of its shares starting from November 17, 2025 [1] - This decision is based on the approval from shareholders at the annual general meeting held on June 6, 2025 [1] - The board may increase the maximum repurchase amount depending on market conditions and will announce any changes in accordance with listing rules [1] Group 2: Market Reaction - Following the announcement, the stock price of 朝聚眼科 rose by 4.07%, reaching HKD 2.56, with a trading volume of HKD 1.3851 million [1]

智通财经APP获悉，朝聚眼科(02219)涨超4%，截至发稿，涨4.07%，报2.56港元，成交额138.51万港 元。 消息面上，朝聚眼科发布公告，于2025年11月17日，董事会已决议根据公司股东于2025年6月6日举行的 股东周年大会上批准的股份购回授权及(如适用)其后股东不时批准的任何更新或重新订立的股份购回授 权，自2025年11月17日起不时于公开市场购回最多价值5000万港元的公司股份。 公司认为，进行股份购回可展示公司对自身业务展望及前景充满信心，且最终将会为公司带来裨益及为 其股东创造价值。根据市况，董事会可不时增加股份购回授权项下的最高购买总额。倘董事会决定增加 最高购回金额，公司将于必要时根据上市规则作出及时公告。 ...

格隆汇11月18日丨朝聚眼科(02219.HK)发布公告，2025年11月17日，董事会已决议根据股份购回授权， 自2025年11月17日起不时于公开市场购回最多价值5000万港元的公司股份。 ...

Core Viewpoint - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan to repurchase up to HKD 50 million worth of its shares starting from November 17, 2025, following approval from shareholders at the annual general meeting on June 6, 2025 [1] Group 1 - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - The board may increase the maximum buyback amount based on market conditions, with timely announcements made as necessary according to listing rules [1] - The company asserts that its current financial resources are sufficient to implement the share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company, Chaoyue Eye Care (02219), has announced a share buyback program, indicating confidence in its business outlook and potential to create value for shareholders [1] Summary by Sections Share Buyback Authorization - The board of directors has resolved to repurchase up to HKD 50 million worth of company shares starting from November 17, 2025, based on the authorization approved at the annual general meeting on June 6, 2025 [1] - The board may increase the maximum purchase amount under the buyback authorization depending on market conditions, with timely announcements to be made as necessary [1] Financial Position - The board believes that the company's existing financial resources are sufficient to implement the share buyback while maintaining a robust financial position [1]